Viracta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch VIRX and buy or sell other stocks, ETFs, and their options commission-free!

About VIRX

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. 

CEO
Craig R. Jalbert
CEOCraig R. Jalbert
Employees
40
Employees40
Headquarters
Cardiff, California
HeadquartersCardiff, California
Founded
1998
Founded1998
Employees
40
Employees40

VIRX Key Statistics

Market cap
874.37K
Market cap874.37K
Price-Earnings ratio
-0.02
Price-Earnings ratio-0.02
Dividend yield
—
Dividend yield—
Average volume
112.77K
Average volume112.77K
High today
$0.023
High today$0.023
Low today
$0.0156
Low today$0.0156
Open price
$0.0165
Open price$0.0165
Volume
129.20K
Volume129.20K
52 Week high
$0.90
52 Week high$0.90
52 Week low
$0.008
52 Week low$0.008
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.